You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Cytokine-Targeted Therapy for Patients With COVID-19: From Guidelines to Latest Developments

  • Authors: Ivan O. Rosas, MD; Paolo A. Ascierto, MD; Puja Mehta, MD
  • CPD Released: 11/20/2020
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 11/20/2021
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US critical care specialists, rheumatologists, and ID/HIV specialists.

The goal of this activity is to educate physicians on the current guideline recommendations regarding the use of cytokine-targeted therapies for patients with coronavirus disease 2019 (COVID-19) and the most recent clinical trial outcomes data with these drugs.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Current understanding of COVID-19-associated hyperinflammation 
    • Current treatment guidelines for severe or critically ill patients with COVID-19 
    • Latest evidence from clinical trials with immunomodulatory therapies for patients with COVID-19 


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Ivan O. Rosas, MD

    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts, United States

    Disclosures

    Disclosure: Ivan O. Rosas, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Genentech, Inc.
    Received grants for clinical research from: Genentech, Inc.

  • Paolo A. Ascierto, MD

    Director, Melanoma Unit
    Cancer Immunotherapy and Innovative Therapy
    National Tumor Institute Fondazione G. Pascale
    Naples, Italy

    Disclosures

    Disclosure: Paolo A. Ascierto, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Alkermes, Inc.; AstraZeneca Pharmaceuticals LP; Array; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Eisai Inc.; Idera; Immunocore; Incyte Corporation; Italfarmaco; MedImmune Inc.; Merck & Co., Inc.; Merck Serono; Nektar; Novartis Pharmaceuticals Corporation; Pierre Fabre; Regeneron Pharmaceuticals, Inc.; Roche-Genentech, Inc.; Sandoz; Sanofi; Sunpharma; Syndaz   
    Received grants for clinical research from: Array; Bristol Myers Squibb Company; Roche-Genentech, Inc.
    Owns stock, stock options, or bonds from: Primevax

  • Puja Mehta, MD

    Department of Rheumatology
    University College London Hospital
    London, United Kingdom

    Disclosures

    Disclosure: Puja Mehta, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Sobi
    Received grants for clinical research from: GlaxoSmithKline

Editor

  • Shanthi Voorn, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Shanthi Voorn, PhD, has disclosed no relevant financial relationships.

Content Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Cytokine-Targeted Therapy for Patients With COVID-19: From Guidelines to Latest Developments

Authors: Ivan O. Rosas, MD; Paolo A. Ascierto, MD; Puja Mehta, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 11/20/2020

Valid for credit through: 11/20/2021

processing....

aHR = adjusted HR
ALT = alanine aminotransferase
ARD = median absolute risk difference
AST = aspartate aminotransferase
AUC = area under plasma concentration-time curve from time 0 to infinity
BACC = Boston Area COVID-19 Consortium
CAR-T = chimeric antigen receptor T-cells
CD = cluster of differentiation
cHIS = COVID-19 associated hyperinflammatory syndrome
CL = plasma clearance
Cmax = maximum plasma concentration
COVID-19 = coronavirus disease 2019
CRP = C-reactive protein
CRS = cytokine release syndrome
CSS = cytokine storm syndrome
CT = computed tomography
ESR = erythrocyte sedimentation rate
fHLH = familial hemophagocytic lymphohistiocytosis
FiO2 = fractional inspired oxygen
GGT = glutamic oxaloacetic transaminase
GM-CSF = granulocyte-macrophage colony-stimulating factor
HIV = human immunodeficiency virus
ICU = intensive care unit
IIT = investigator-initiated trial
IL = interleukin
IV = intravenous
JAK = janus kinase
MALS = macrophage activation-like syndrome
MAS = macrophage activation syndrome
MV = mechanical ventilation
NHS = National Health Service
NIV = noninvasive ventilation
NK = natural killer
NLR = neutrophil to lymphocyte ratio
OR = odds ratio
PaO2 = partial pressure of oxygen
PLT = platelet
R = randomization
RCT = randomized controlled trial
RD = risk difference
REMAP-CAP = Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
RR = rate ratio
SARS-CoV-2 = severe respiratory syndrome coronavirus 2
sHLH = secondary hemophagocytic lymphohistiocytosis
SOC = standard of care
SPO2 = oxygen saturation
TCZ = tocilizumab
Tmax = time at which Cmax occurred
WHO = World Health Organization
WHO-CPS = WHO 10-point clinical progression scale

« Return to: Cytokine-Targeted Therapy for Patients With COVID-19: From Guidelines to Latest Developments
  • Print